Peak Pharma Revenue, Profits - PKPH Quarterly Income Statement

Add to My Stocks
$0.1 $0.02 (16.67%) PKPH stock closing price Sep 18, 2018 (Closing)

Fundamental analysis of PKPH stock involves analyzing its financial statements, apart from checking the Peak Pharma stock price. In the income statement, an investor can look at important parameters like revenue or sales, gross profits, net profits, and EPS basic to gain deeper insights. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue decrease to $- for 2018 Q3 impacts the PKPH stock. Investors typically check year over year or quarter over quarter revenue growth. One also needs to look at Peak Pharma assets, operating expenses and Peak Pharma free cash flow. The Peak Pharma profit and loss statement shows revenue of $- for 2018 Q3. Revenue has decreased by 0 QoQ for PKPH stock.

View and download details of revenue and profits for Peak Pharma for latest & last 40 quarters.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Oct - Sep2018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q2
Peak Pharma Revenues or Net Sales
----------
Cost Of Goods Sold (COGS)----------
Peak Pharma Gross Profit
----------
Research & Development Expense----------
Selling General & Admin Expense----------1.5M
Income Before Depreciation Depletion Amortization--0.01M-0.01M-0.02M-0.01M-0.01M--0.01M-0.01M1.5M
Depreciation Depletion Amortization----------
Non Operating Income------0.01M----
Interest Expense----------
Peak Pharma Pretax Income
--0.01M-0.01M-0.03M-0.01M-0.01M--0.01M-0.01M1.48M
Provision for Income Taxes----------
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations--0.01M-0.01M-0.03M-0.02M-0.01M--0.01M-0.01M1.49M
Extraordinary Items & Discontinued Operations----------
Peak Pharma Profit/ Loss (Net Income)
--0.01M-0.01M-0.03M-0.02M-0.01M--0.01M-0.01M1.49M
Average Shares used to compute Diluted EPS-78.36M--78.36M78.36M78.36M-78.36M79.82M
Average Shares used to compute Basic EPS-78.36M--78.36M78.36M78.36M-78.36M78.36M
Income Before Nonrecurring Items--0.01M---0.02M-0.01M---0.01M1.49M
Income from Nonrecurring Items----------
Peak Pharma Earnings Per Share Basic Net
-0.00--0.000.000.00-0.000.02
Peak Pharma Earnings Per Share Diluted Net
-0.00--0.000.000.00-0.000.02
EPS Diluted Before Nonrecurring Items-0.00--0.000.000.00-0.000.02
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Peak Pharma stock analysis involves checking at least a few of the important things like:

  • Revenue: This is the inflow that is generated from the sale of goods or services and is $- for this quarter of 2018 Q3. Our Peak Pharma revenue chart gives a clear visual representation of how the topline or sales growth has been. Investors often invest only in those companies where the revenue is growing at a steady rate.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $- for Peak Pharma for 2018 Q3. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called the profit and loss statement. Apart from the PKPH income statement, one can check the Peak Pharma historical stock prices to check how the price has moved with time.

Peak Pharma Income Statement - Key Financial Ratios

Other Income Statements - Peak Pharmaceuticals Inc Industry Peers

MYOS RENS income statement, Protalex income statement